ライフサイエンスコーパス: vaccine development

1 hips of large viruses and should aid in ASFV vaccine development.

2 e virus in both seasons may be important for vaccine development.

3 on particle exterior, making them ideal for vaccine development.

4 tein, suggesting this region as a target for vaccine development.

5 Such aspects must be considered to P. vivax vaccine development.

6 algorithms to identify potential targets for vaccine development.

7 passive prophylaxis and aid next-generation vaccine development.

8 nd E2 and the relevance of animal models for vaccine development.

9 ugs and directions for viral attenuation and vaccine development.

10 Matrix-M adjuvant were evaluated to support vaccine development.

11 eding studies of host-virus interactions and vaccine development.

12 c humoral immunity to guide patient care and vaccine development.

13 ly needed to inform therapeutic concepts and vaccine development.

14 tant implications for natural infections and vaccine development.

15 ld be taken into consideration in future HCV vaccine development.

16 ere GAS infections and for future efforts at vaccine development.

17 oton pump inhibitors, adding probiotics, and vaccine development.

18 ution that CHIM studies can make to Shigella vaccine development.

19 ory events post-vaccination could accelerate vaccine development.

20 s (NAbs), such as AR3A, is critical to guide vaccine development.

21 ecedented achievement for noninfluenza viral vaccine development.

22 ransmission monitoring tools and for subunit vaccine development.

23 ate NS1 as an important candidate for dengue vaccine development.

24 nza B virus antibodies is required to inform vaccine development.

25 Numerous challenges have impeded HIV-1 vaccine development.

26 rix-M(TM) adjuvant were evaluated to support vaccine development.

27 accines could be harnessed to facilitate GBS vaccine development.

28 perhaps the greatest challenge to successful vaccine development.

29 s; therefore, EBV is an important target for vaccine development.

30 ocess for immune evasion, raising issues for vaccine development.

31 s, also mentioning possible implications for vaccine development.

32 c development and provide insights into hMPV vaccine development.

33 vaccine characteristics to inform strategic vaccine development.

34 for intestinal immune-mediated diseases and vaccine development.

35 the HCV envelope proteins is one approach to vaccine development.

36 nce their function is therefore critical for vaccine development.

37 for patient risk stratification and possibly vaccine development.

38 N01 epitope as a candidate for lineage-based vaccine development.

39 te an antigenic conformation optimal for HIV vaccine development.

40 ites targeted by these MAbs could inform HCV vaccine development.

41 d many are important in mucosal immunity and vaccine development.

42 should be useful for anti-SFTSV therapy and vaccine development.

43 dvantageous in the context of glycoconjugate vaccine development.

44 andidates have provided a roadmap for future vaccine development.

45 es have moved to the center stage of malaria vaccine development.

46 potential for HIV-1 prevention, therapy, and vaccine development.

47 ossible the exploration of new templates for vaccine development.

48 p potentially simplified approaches to HIV-1 vaccine development.

49 of IC31 to enable dose selection for further vaccine development.

50 the usage of these antibodies and facilitate vaccine development.

51 y impact antibody responses is essential for vaccine development.

52 has been one of the major challenges to RSV vaccine development.

53 ventions for targeted populations, including vaccine development.

54 l vaccines justifies the substantial cost of vaccine development.

55 ain, providing an invaluable tool to support vaccine development.

56 d indicate an alternative approach for HIV-1 vaccine development.

57 d protection is greatly needed for influenza vaccine development.

58 nd evolving, and is a major challenge to HIV vaccine development.

59 uman cytomegalovirus (HCMV) pathogenesis and vaccine development.

60 isorders, liver pathogeneses, and efforts in vaccine development.

61 ines, which are widely used for research and vaccine development.

62 M. tuberculosis exposure and age can inform vaccine development.

63 ilitating disease diagnostics, treatment and vaccine development.

64 dy-mediated mucosal immunity while informing vaccine development.

65 odies (bNAbs) against HCV is a major goal of vaccine development.

66 linical and clinical applications in malaria vaccine development.

67 Thus, they are attractive immunogens for vaccine development.

68 ralizing epitope, which can be exploited for vaccine development.

69 s of such features is essential for rational vaccine development.

70 ZIKV CHIM could de-risk and accelerate ZIKV vaccine development.

71 understanding cellular immunity for targeted vaccine development.

72 nistering membrane-bound proteins for future vaccine development.

73 eaved to (gp120/gp41)3] poses challenges for vaccine development.

74 Ps and labile thiolactone bond have hindered vaccine development.

75 e of specific epitopes is critical for HIV-1 vaccine development.

76 Application and utility of mass cytometry in vaccine development.

77 tions appears discordant with strategies for vaccine development.

78 en the major focus of research in individual vaccine development.

79 aracterization of NAb interactions can guide vaccine development.

80 the design of small molecule inhibitors and vaccine development.

81 optimal candidates for diagnostic assays and vaccine development.

82 ication provide a useful model to inform HIV vaccine development.

83 he primary neutralizing antigen critical for vaccine development.

84 l diseases with a focus on new paradigms for vaccine development.

85 s not expected to be an obstacle for current vaccine development.

86 d identify suitable targets for antiviral or vaccine development.

87 enesis and is therefore a primary target for vaccine development.

88 ate the global pace of clinical tuberculosis vaccine development.

89 support efforts to target these proteins for vaccine development.

90 has proven to be a significant challenge for vaccine development.

91 nd their genetic diversity may influence GBS vaccine development.

92 ed congenital infections have prompted rapid vaccine development.

93 ed human infection studies to accelerate HCV vaccine development.

94 ns of pathogenesis, virulence regulation and vaccine development.

95 isms have been the major focus in individual vaccine development.

96 view of progress in the field of Ebola virus vaccine development.

97 antigenicity, which is critical to influenza vaccine development.

98 provide valuable insights into antiviral and vaccine development.

99 h applications in flavivirus diagnostics and vaccine development.

100 potential to identify novel drug targets and vaccine development.

101 tes are prime targets of blood stage malaria vaccine development.

102 D-19), including epidemiological studies and vaccine development.

103 galovirus (CMV) supports current interest in vaccine development.

104 lication of an RHV outbred rat model for HCV vaccine development.

105 These results support continued vaccine development.

106 nically distinct isolates is a challenge for vaccine development.

107 ncept of the reverse vaccinology approach to vaccine development.

108 hich would significantly accelerate rational vaccine development.

109 ing preventive measures, including norovirus vaccine development.

110 uable tools for immunological evaluation and vaccine development.

111 odiagnosis, convalescent plasma therapy, and vaccine development.

112 ctive antibodies is a critical goal of HIV-1 vaccine development.

113 development of CD8(+) memory T cells during vaccine development.

114 t giant virus assembly and paves the way for vaccine development.

115 of OMVs could serve as a robust approach for vaccine development.

116 come current challenges hindering successful vaccine development.

117 so a potential antigen for immunotherapy and vaccine development.

118 latory neoantigen targets hastens neoantigen vaccine development.

119 or novel immunotherapy and tuberculosis (TB) vaccine development.

120 t of novel antimalarial therapies and inform vaccine development.

121 onal tools to enhance influenza research and vaccine development.

122 cess an attractive target for therapeutic or vaccine development.

123 maceuticals characterization, and antiglycan vaccine development.

124 ant subtype, with potential implications for vaccine development.

125 RSV is a priority for vaccine development.

126 ngoing population-level RSV surveillance and vaccine development.

127 tudying fusion, which identifies targets for vaccine development.

128 strains on hospitals and providing time for vaccine development.

129 ax infection and discuss current progress in vaccine development.

130 of B. pertussis is an attractive antigen for vaccine development.

131 y, and limited treatment accessibility makes vaccine development a high priority.

132 tile vector with high safety for recombinant vaccine development, addressing unmet medical needs.

133 s viral entry into cells and is critical for vaccine development against coronavirus disease 2019 (CO

134 which could have important implications for vaccine development against flagellated microbial pathog

135 ing to the development of a novel vector for vaccine development against infectious diseases and canc

136 Our findings can also be applied to vaccine development against other flaviviruses, such as

137 nt and broader implications for immunity and vaccine development against pathogenic Salmonellae.

138 serve as promising targets for peptide-based vaccine development against this emerging global pathoge

139 Vaccine development against tuberculosis (TB) is based o

140 HIV-1 vaccine development aims to elicit broadly neutralizing

141 ivo that may have important implications for vaccine development and autoimmunity.

142 LA) class II molecules would be valuable for vaccine development and cancer immunotherapies.

143 response, characteristics that have stymied vaccine development and cause people living in endemic r

144 vation could have important ramifications in vaccine development and clinical care.

145 capture IAV diversity that will be used for vaccine development and cultivate a more thorough unders

146 despite substantial investment into drug and vaccine development and deployment.

147 d highlights the increasing challenge to HIV vaccine development and diagnostic, drug resistance, and

148 influenza virus antigenicity is critical to vaccine development and disease prevention.

149 Rational vaccine development and evaluation requires identifying

150 ue to identify protective profile useful for vaccine development and for pathogenesis studies.

151 (KI) mouse models play an important role in vaccine development and fundamental immunological studie

152 This approach has rejuvenated the field of vaccine development and has fostered hope that new ways

153 We outline the progress in vaccine development and highlight important directions f

154 re, we review current approaches to COVID-19 vaccine development and highlight the role of nanotechno

155 urrent epidemiologic situation and status of vaccine development and highlights questions to be addre

156 n of an insect-specific virus in preclinical vaccine development and highlights the potential applica

157 to overcoming the challenges associated with vaccine development and identification of novel strategi

158 These results have implications for vaccine development and immune surveillance.

159 d also aided in extending studies focused on vaccine development and immunity.

160 nanocarriers with potential applications in vaccine development and immunotherapy.

161 should be a key factor to prioritise in EBV vaccine development and included in vaccine TPPs.

162 1 and be utilized as indicators for improved vaccine development and informed vaccination strategies.

163 interventions for SARS-CoV-2 with a focus on vaccine development and its challenges.

164 predictions improve while the lead-time for vaccine development and other interventions decreases.

165 implications of these findings for COVID-19 vaccine development and our approach to optimizing for s

166 results have important implications for ZIKV vaccine development and provide a mouse model for evalua

167 responsible for pathogen protection enables vaccine development and provides insights into host defe

168 on RSV infection in BPD patients, including vaccine development and RSV-specific treatment.

169 glycoproteins has critical implications for vaccine development and suggests that similar phenomena

170 cosal tissue may prove critical to effective vaccine development and the prophylactic use of monoclon

171 s for diagnosis, public health surveillance, vaccine development and the selection of convalescent pl

172 nano-carriers and antigen-display systems in vaccine development and therapeutic applications.

173 nthelminthic drugs are needed, together with vaccine development and tools for diagnosis and assessme

174 BOV and summarize the current status of EBOV vaccine development and treatment of EVD.

175 that nsp16 can be a universal target for CoV vaccine development and will aid in the development of v

176 4bs) by vaccination is an important goal for vaccine development and yet to be achieved.

177 y has been a major concern for epidemiology, vaccine development, and antibody-based drug therapy.

178 essment of the immune status of individuals, vaccine development, and basic biology.

179 variants with enhanced stability for use in vaccine development, and discovery of new stability-modu

180 EnvGP may not be an ideal candidate for HCV vaccine development, and discrete domains within E2 may

181 onsider the implications of this linkage for vaccine development, and discuss modulating tolerance as

182 lla biology and pathogenesis, immunology and vaccine development, and genomics and evolution.

183 ormation for future surveillance, diagnosis, vaccine development, and prediction of EV-D68-associated

184 s that can be modified to attenuate ANDV for vaccine development, and suggest the potential for kinas

185 g antibodies (bNAbs) remains a challenge for vaccine development, and the potential of passively deli

186 nderstanding the pathogenesis of SARS-CoV-2, vaccine development, and therapeutic testing.

187 has implications for immunization programs, vaccine development, and tuberculosis control efforts wo

188 hree topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering,

189 ce a functional recombinant MOMP protein for vaccine development are limited by poor solubility, low

190 troviral therapy, diagnostic approaches, and vaccine development are providing novel tools for treatm

191 protective immune responses are essential to vaccine development as they can provide selection criter

192 r findings also suggest a promising means of vaccine development based on surface-exposed outer-membr

193 s for studies of dengue pathogenesis and for vaccine development, because enhancement, not just lack

194 e and nonhuman primates have been crucial in vaccine development but have not defined the duration of

195 utility of the BLT humanized mouse for HIV-1 vaccine development but suggest that additional improvem

196 e data has the potential to advance rational vaccine development but yet there are no licensed vaccin

197 lizing antibodies (bnAbs) is a goal of HIV-1 vaccine development, but current vaccine strategies have

198 to be a promising potential approach to HCV vaccine development, but they raise substantial ethical

199 have potential to inform new strategies for vaccine development by identifying bNAb combinations in

200 lored the utility of the BLT model for HIV-1 vaccine development by immunizing BLT mice against the c

201 This study supports future blood-stage vaccine development by providing a solid methodology to

202 of a vaccine, and we can learn from previous vaccine development campaigns.

203 015-2016 Zika epidemics prompted accelerated vaccine development, decision makers need to know the po

204 The rapid progress in vaccine development demonstrates the capacity of governm

205 RTANCE MVA is an attractive viral vector for vaccine development due to its safety and immunogenicity

206 an integral tool for antibody discovery and vaccine development efforts against a wide range of anti

207 These data will inform ongoing human ZIKV vaccine development efforts and enhance our understandin

208 Although numerous drug and vaccine development efforts are underway, there are many

209 n.IMPORTANCE Our results are relevant to HIV vaccine development efforts because they suggest that in

210 Vaccine development efforts have recently focused on ena

211 Continued vaccine development efforts will lead to secure supply o

212 influenza, dengue, and others) have resisted vaccine development efforts, largely because of the fail

213 e focus of the current "universal" influenza vaccine development efforts.

214 STLV-infected baboons as a model system for vaccine development efforts.

215 is approach as a potential addition to Ebola vaccine development efforts.IMPORTANCE Ebola outbreaks r

216 ynthetic glycans, to be used in diagnostics, vaccine development, enzyme characterization and structu

217 em as an alternative platform for flavivirus vaccine development, especially for highly pathogenic fl

218 Vaccine development focuses on the principal target of t

219 support for TCV highlights the challenges of vaccine development for lower-income countries and the i

220 roteins, as well as antibody prophylaxis and vaccine development for RSV.

221 However, vaccine development has been confounded because of HCV's

222 Malaria vaccine development has been dominated by the subunit ap

223 Vaccine development has been hampered by the lack of imm

224 Influenza vaccine development has largely focused on the hemagglut

225 Rapid vaccine development has led to a number of candidates ca

226 Decades of TB vaccine development have focused on adaptive T cell immu

227 ce have been the stalwart of therapeutic and vaccine development; however, they do not support infect

228 review discusses the storied history of RSV vaccine development, immunological lessons learned along

229 Our results may have vaccine development implications including whether speci

230 r usage, with important implications for HCV vaccine development.IMPORTANCE Hepatitis C virus (HCV) i

231 tion system as a new platform for flavivirus vaccine development.IMPORTANCE Many flaviviruses are sig

232 results highlight the value of ZIKV NS1 for vaccine development.IMPORTANCE Most Zika virus (ZIKV) va

233 e number of sites that could be targeted for vaccine development.IMPORTANCE Worldwide, more than 70 m

234 and highlight the challenges for successful vaccine development in each phase.

235 Despite promising progress in malaria vaccine development in recent years, an efficacious subu

236 unology has not thus far contributed much to vaccine development, in that most of the vaccines we use

237 Significant hurdles to vaccine development include host range specificity, maki

238 Novel approaches to vaccine development include structure-based immunogen de

239 such molecular switches will be critical for vaccine development, interpretation of vaccine efficacy

240 tive immunity to SARS-CoV-2 is important for vaccine development, interpreting coronavirus disease 20

241 Traditionally, vaccine development involves tradeoffs between immunogen

242 A major goal for HIV-1 vaccine development is an ability to elicit strong and d

243 Tuberculosis vaccine development is difficult and slow.

244 Vaccine development is focused on the principal target o

245 A major challenge for vaccine development is focusing the immune response on c

246 S) infection causes a range of diseases, but vaccine development is hampered by the high number of se

247 n E protein monomers.IMPORTANCE Dengue virus vaccine development is particularly challenging because

248 Vaccine development is proceeding at an unprecedented pa

249 A major challenge in dengue vaccine development is that cross-reactive anti-DENV Abs

250 A major goal of HIV-1 vaccine development is the design of immunogens that ind

251 A persistent goal of vaccine development is the enhancement of the immunogeni

252 A goal of vaccine development is therefore to mimic the closed con

253 A strategy for HIV-1 vaccine development is to define envelope (Env) evolutio

254 A goal of HIV vaccine development is to elicit antibodies with neutral

255 A promising approach for vaccine development is to generate, through codon pair d

256 One goal of HIV-1 vaccine development is to induce antibodies that are sim

257 berculosis immunopathogenesis and facilitate vaccine development is urgently needed.Objectives: We ev

258 While vaccine development is warranted, a licensed vaccine, sp

259 t STriTuVaD-In Silico Trial for Tuberculosis Vaccine Development-is supporting the identification of

260 Despite advances in vaccine development, it remains unclear how ZIKV vaccina

261 amine two realistic new aspects pertinent to vaccine development: loss in B cell diversity across suc

262 and therefore could be a target for drug or vaccine development.Many strains of Plasmodium differ in

263 Hence, considering the 3Ds in vaccine development may allow for enhancement of their a

264 A more productive approach for vaccine development may be complete deletion of specific

265 al model of the disease, tools to facilitate vaccine development must be identified.

266 oof of principle that can inform prospective vaccine development not only for gonorrhoea but also for

267 There are numerous hurdles in vaccine development, of which knowing the appropriate im

268 aches to current gonorrhea treatment such as vaccine development or novel therapeutics.

269 e manipulation of B cell differentiation for vaccine development or to treat diseases where antibodie

270 efficient CD8 T cell response profiling for vaccine development, particularly for pathogens with com

271 xpressed M2e soluble proteins as a promising vaccine development platform.

272 for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential o

273 Based on prior flavivirus vaccine development programs, knowledge of flavivirus pa

274 human immunodeficiency virus type 1 (HIV-1) vaccine development programs.

275 Vaccine development requires production, in quantities s

276 argeting of antibodies similar to 2C6 during vaccine development should be considered.

277 S1 protein may be an alternative antigen for vaccine development, since antibodies to NS1 do not bind

278 There is no approved HCMV vaccine, and vaccine development strategies are complicated by eviden

279 Tuberculosis vaccine development strategies mostly target infants or

280 ects on chronic pathology, natural immunity, vaccine development strategies, immune disorders, and dr

281 on suggesting that PvMSP1P may be useful for vaccine development strategy for specific single epitope

282 HN13 LTA is an attractive target for future vaccine-development studies.

283 ishing common procedures to advance Shigella vaccine development, support licensure, and ultimately f

284 tribute to a pool of peptides identified for vaccine development that can be tested in vitro to confi

285 the current focus of immunogen design in HCV vaccine development; thus, making E1E2 both scientifical

286 , and the importance of strain selection for vaccine development to control H5N1 HPAIV in the agricul

287 Progress in SARS-CoV-2 vaccine development to date has been faster than for any

288 Current efforts are focused in part on vaccine development to induce such MARV-neutralizing Abs

289 sults provide a roadmap for structure-guided vaccine development to maximize antibody efficacy agains

290 Although vaccine development to modify this congenital infection

291 s on how new and more rational approaches to vaccine development use novel biotechnology, target new

292 ted success rates and timelines for COVID-19 vaccine development vary.

293 Ebola vaccine development was accelerated in response to the 2

294 the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated.

295 al target in next-generation influenza virus vaccine development.We found that antibodies against neu

296 zation and suggests a roadmap for SARS-CoV-2 vaccine development, which can be generalizable to other

297 irals, and the elimination of bottlenecks in vaccine development, will be essential to containing and

298 will review the advances in whole-sporozoite vaccine development with a particular focus on genetical

299 , we review the progress made in NiV and HeV vaccine development, with an emphasis on those approache

300 ies help to fill critical knowledge gaps for vaccine development, yet study design and methodological